FLUTICASONE PROPIONATE ( DrugBank: Fluticasone propionate, Fluticasone )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 98 | Eosinophilic gastrointestinal disease | 11 |
| 228 | Bronchiolitis obliterans | 2 |
98. Eosinophilic gastrointestinal disease
Clinical trials : 171 / Drugs : 184 - (DrugBank : 47) / Drug target genes : 42 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05083312 (ClinicalTrials.gov) | September 30, 2021 | 6/10/2021 | Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial | An Adolescent Sub-study Within FLUTE-2: A Randomized, Double-blind, Placebo-Controlled Study of APT-1011 (Fluticasone Propionate Oral Dispersible Tablet Formulation), With an Open-label Extension, in Adolescent Subjects With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: APT-1011;Drug: Placebo oral tablet | Ellodi Pharmaceuticals, LP | NULL | Recruiting | 12 Years | 17 Years | All | 30 | Phase 3 | United States;Australia |
| 2 | EUCTR2019-001521-27-DE (EUCTR) | 03/08/2020 | 10/02/2020 | Study with Eosinophilic Esophagitis subjects | Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects with Eosinophilic Esophagitis - FLUTE-2 | Eosinophilic Esophagitis MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: APT-1011 Product Code: APT-1011 - 3 mg INN or Proposed INN: Fluticasone Propionate, USP Other descriptive name: FLUTICASONE PROPIONATE | Adare Pharmaceuticals US, LP | NULL | Not Recruiting | Female: yes Male: yes | 120 | Phase 3 | United States;Spain;Australia;Germany | ||
| 3 | EUCTR2019-001521-27-ES (EUCTR) | 04/04/2020 | 28/02/2020 | Study with Eosinophilic Esophagitis subjects | Fluticasone propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 in Adult and Adolescent Subjects with Eosinophilic Esophagitis - FLUTE-2 | Eosinophilic Esophagitis MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: APT-1011 Product Code: APT-1011 - 3 mg INN or Proposed INN: Fluticasone Propionate, USP Other descriptive name: FLUTICASONE PROPIONATE | Adare Pharmaceuticals US, LP | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 120 | Phase 3 | United States;Spain;Australia;Germany;Switzerland | ||
| 4 | NCT04281108 (ClinicalTrials.gov) | January 30, 2020 | 20/2/2020 | Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) | Fluticasone Propionate Oral Dispersible Tablet Formulation in Eosinophilic Esophagitis: A Two-Part, Randomized, Double-blind, Placebo-Controlled Study of APT-1011 With an Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: APT-1011;Drug: Placebo oral tablet | Ellodi Pharmaceuticals, LP | NULL | Active, not recruiting | 18 Years | N/A | All | 143 | Phase 3 | Germany;United States;Spain;Australia |
| 5 | EUCTR2016-004749-10-DE (EUCTR) | 15/11/2017 | 26/07/2017 | study in subjects with Eosinophilic Esophagitis | FLUTicasone in Eosinophilic esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose ranging, and Maintenance Study of APT-1011 in Subjects with Eosinophilic Esophagitis. | Eosinophilic Esophagitis MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: APT-1011 INN or Proposed INN: FLUTICASONE PROPIONATE Other descriptive name: FLUTICASONE PROPIONATE Product Name: APT-1011 Other descriptive name: FLUTICASONE PROPIONATE Product Name: APT-1011 Other descriptive name: FLUTICASONE PROPIONATE | Adare Pharmaceutical | NULL | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | United States;Canada;Spain;Belgium;Germany;Switzerland | ||
| 6 | EUCTR2016-004749-10-BE (EUCTR) | 06/10/2017 | 07/07/2017 | study in subjects with Eosinophilic Esophagitis | FLUTicasone in Eosinophilic esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose ranging, and Maintenance Study of APT-1011 in Subjects with Eosinophilic Esophagitis. | Eosinophilic Esophagitis MedDRA version: 20.1;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: APT-1011 INN or Proposed INN: FLUTICASONE PROPIONATE Other descriptive name: FLUTICASONE PROPIONATE Product Name: APT-1011 Other descriptive name: FLUTICASONE PROPIONATE Product Name: APT-1011 Other descriptive name: FLUTICASONE PROPIONATE | Adare Pharmaceutical | NULL | Not Recruiting | Female: yes Male: yes | 100 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United States;Canada;Spain;Belgium;Germany;Switzerland | ||
| 7 | EUCTR2016-004749-10-ES (EUCTR) | 20/09/2017 | 20/09/2017 | study in subjects with Eosinophilic Esophagitis | FLUTicasone in Eosinophilic esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose ranging, and Maintenance Study of APT-1011 in Subjects with Eosinophilic Esophagitis. | Eosinophilic Esophagitis MedDRA version: 20.0;Level: LLT;Classification code 10064220;Term: Eosinophilic esophagitis;System Organ Class: 100000013492;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Product Name: APT-1011 INN or Proposed INN: Fluticasone Propionate Other descriptive name: FLUTICASONE PROPIONATE Product Name: APT-1011 INN or Proposed INN: Fluticasone Propionate Other descriptive name: FLUTICASONE PROPIONATE Product Name: APT-1011 INN or Proposed INN: Fluticasone Propionate Other descriptive name: FLUTICASONE PROPIONATE | Adare Pharmaceutical | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 100 | Phase 2 | United States;Canada;Belgium;Spain;Germany | ||
| 8 | NCT02778867 (ClinicalTrials.gov) | May 20, 2016 | 12/10/2015 | SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study | Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial | Eosinophilic Gastrointestinal Disorders (EGIDs);Eosinophilic Esophagitis (EoE) | Other: 1 Food Elimination Diet Therapy;Other: 6 Food Elimination Diet Therapy;Other: 6 Food Elimination Diet (after 1FED failure);Drug: Fluticasone Propionate, 880 mcg twice daily (after 6FED failure) | Children's Hospital Medical Center, Cincinnati | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);National Institute of Allergy and Infectious Diseases (NIAID);Office of Rare Diseases (ORD);National Center for Advancing Translational Science (NCATS) | Completed | 18 Years | 60 Years | All | 129 | Phase 2/Phase 3 | United States |
| 9 | NCT02610816 (ClinicalTrials.gov) | March 21, 2016 | 12/10/2015 | Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids | Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids | Eosinophilic Esophagitis;Eosinophilic Gastrointestinal Disorders (EGIDs) | Other: 1 Food Elimination Diet;Other: 4 Food Elimination Diet;Other: 4 Food Elimination Diet (post 1FED failure);Drug: Fluticasone Propionate, 800 mcg twice daily (post 4FED failure) | Children's Hospital Medical Center, Cincinnati | Patient-Centered Outcomes Research Institute | Completed | 6 Years | 17 Years | All | 67 | Phase 2/Phase 3 | United States |
| 10 | NCT00426283 (ClinicalTrials.gov) | January 2007 | 22/1/2007 | A Study of Flovent in Patients With Eosinophilic Esophagitis | A Double Blinded, Randomized Trial of Swallowed 1760mcg Fluticasone Propionate Versus Placebo in the Treatment of Eosinophilic Esophagitis | Eosinophilic Esophagitis | Drug: Flovent;Other: Placebo | Marc Rothenberg, MD | NULL | Completed | 3 Years | 30 Years | All | 42 | Phase 2 | United States |
| 11 | NCT00266578 (ClinicalTrials.gov) | October 2002 | 15/12/2005 | A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders | Effect of Swallowed Fluticasone Propionate on Eosinophilic Esophagitis; A Prospective, Randomized, Placebo-Controlled Trial | Eosinophilic Esophagitis | Drug: Fluticasone Propionate | Marc Rothenberg | NULL | Completed | 3 Years | 30 Years | Both | 30 | Phase 3 | United States |
228. Bronchiolitis obliterans
Clinical trials : 96 / Drugs : 125 - (DrugBank : 34) / Drug target genes : 33 - Drug target pathways : 155
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04655508 (ClinicalTrials.gov) | May 21, 2021 | 10/11/2020 | Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 =10% From Pre Transplantation | Efficacy of Fluticasone Propionate Associated With Salmeterol Using Inhalation Chamber Versus Placebo to Improve the Respiratory Function in Children Over Six Years of Age Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation With a Decline of FEV1 =10% From Pre Transplantation | Stem Cell Transplant Complications;Respiratory Disease;Bronchiolitis Obliterans | Drug: Seretide;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | GlaxoSmithKline | Recruiting | 6 Years | 17 Years | All | 243 | Phase 3 | France |
| 2 | NCT01307462 (ClinicalTrials.gov) | June 2011 | 1/3/2011 | Targeted Therapy of Bronchiolitis Obliterans Syndrome | Fluticasone Propionate, Azithromycin, and Montelukast Sodium in Treating Patients With Bronchiolitis Obliterans Who Previously Underwent Stem Cell Transplant | Bronchiolitis Obliterans | Drug: fluticasone propionate;Drug: montelukast sodium;Drug: azithromycin | Stephanie Lee | National Cancer Institute (NCI) | Completed | 6 Years | 99 Years | All | 36 | Phase 2 | United States |